2023 World Conference on Lung Cancer (Posters)-P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer

P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A comparative effectiveness analysis was conducted to evaluate the use of selpercatinib versus standard therapy in patients with non-small cell lung cancer (NSCLC) with RET fusion. The study aimed to fill the data gap in head-to-head comparisons between selpercatinib and standard therapy in previously untreated patients. The findings were based on a post hoc case-matched analysis using data from the LIBRETTO-001 trial.<br /><br />The analysis included patients aged 18 and above with a diagnosis of RET fusion-positive advanced NSCLC and an Eastern Cooperative Oncology Group Performance Status score of 2. Treatment initiation with selpercatinib or standard therapies served as the index date, and outcomes such as time to treatment discontinuation (TTD), time to next treatment or death (TTNT-D), and time to progression (TTP) were assessed.<br /><br />After propensity score-matching, 138 patients in the comparator arm were matched to 69 patients in the selpercatinib arm. The baseline characteristics between the two arms were similar. The results showed that patients in the selpercatinib arm had longer TTD, TTNT-D, and TTP compared to those in the comparator arm. The hazard ratios (HR) for these outcomes were reported as 0.26 (95% CI: 0.18, 0.38) for TTD, 0.13 (95% CI: 0.07, 0.24) for TTNT-D, and 0.42 (95% CI: 0.29, 0.61) for TTP.<br /><br />The findings suggest that selpercatinib may be more effective as a first-line therapy compared to standard therapies in patients with RET fusion-positive NSCLC. However, due to the immaturity of the data, caution is warranted in interpreting the results.<br /><br />In conclusion, this comparative effectiveness analysis provides evidence of improved effectiveness associated with first-line use of selpercatinib in patients with RET fusion-positive NSCLC. The results contribute to the understanding of treatment options for metastatic NSCLC, particularly in the context of targeted therapy.

Asset Subtitle

Daniel Tan

Meta Tag

Speaker Daniel Tan

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

comparative effectiveness analysis

selpercatinib

standard therapy

NSCLC

RET fusion

head-to-head comparisons

first-line therapy

metastatic NSCLC

targeted therapy

LIBRETTO-001 trial